医学
回顾性队列研究
急性呼吸窘迫
甲基强的松龙
地塞米松
糖皮质激素
队列研究
呼吸窘迫
急诊医学
队列
内科学
急性呼吸衰竭
重症监护医学
皮质类固醇
真实世界的证据
儿科
年轻人
重症监护室
重症监护
梅德林
呼吸衰竭
数据库
选择(遗传算法)
作者
Jiayang Huang,Zhikun Xu,Jiajia Huang,Jianwen Huang,Guibao Zhou,Wei Xiong,Shunyao Xu,Jun Li,YouLian Chen,Silin Liang,Linling He,Huaisheng Chen,Xia Liu,Chengying Hong
出处
期刊:Shock
[Lippincott Williams & Wilkins]
日期:2026-03-27
卷期号:66 (1): 58-68
标识
DOI:10.1097/shk.0000000000002815
摘要
BACKGROUND: The comparative effectiveness of specific glucocorticoids (methylprednisolone, hydrocortisone, and dexamethasone) and the impact of dosing intensity on outcomes in sepsis-associated acute respiratory distress syndrome (ARDS) remain poorly characterized. METHODS: This retrospective cohort study analyzed adults with sepsis-associated ARDS from the Medical Information Mart for Intensive Care IV database. Patients were classified by glucocorticoid type and dose (low-dose: <88 mg/day methylprednisolone equivalent; high-dose: ≥88 mg/day). The primary outcome was 28-day mortality, analyzed using multivariable Cox models with hazard ratio (HR) and 95% confidence interval (CI). Subgroup analyses and propensity score matching (PSM) were performed to validate the findings. RESULTS: Among 896 patients, 443 (49.4%) died within 28 days. Compared with hydrocortisone, both methylprednisolone (adjusted HR = 0.71, 95% CI 0.57-0.89) and dexamethasone (adjusted HR = 0.61, 95% CI 0.44-0.86) were associated with lower 28-day mortality. High-dose therapy was associated with increased mortality versus low-dose (adjusted HR = 1.56, 95% CI 1.23-1.97). Results were consistent across subgroups and in PSM analyses. CONCLUSION: In sepsis-associated ARDS, glucocorticoid selection and dose are associated with survival. Methylprednisolone and dexamethasone were associated with lower mortality compared with hydrocortisone, while high-dose therapy was linked to increased mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI